Fig. 4: Antitumour activity and tumour-specific immune response in prophylactic mouse model. | Nature Communications

Fig. 4: Antitumour activity and tumour-specific immune response in prophylactic mouse model.

From: A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity

Fig. 4

a Scheme of (MS@OVAinMOF)@(anti-CTLA4inMOF) fabrication. b Timeline of experiment: female C57Bl/6J mice were immunised with subcutaneous injection of cancer vaccines into the left flank three times at 0, 3 and 10 days, challenged with 5 × 105 cells mouse−1 of E.G7-OVA cells into the right flank at 14 day and monitored whether vaccines inhibited tumour growth or not. 1# Saline group; 2# free OVA-anti-CTLA4 group (OVA, 100 μg/mouse; anti-CTLA4 Ab, 20 μg/mouse); 3# (OVAinMOF)@(anit-CTLA4inMOF) group (OVA, 100 μg/mouse; anti-CTLA4 Ab, 20 μg/mouse; MOF, 600 μg/mouse); and 4# (MS@OVAinMOF)@(anti-CTLA4inMOF) (OVA, 100 μg/mouse; anti-CTLA4 Ab, 20 μg/mouse; MS@MOF, 600 μg/mouse). c (MS@OVAinMOF)@(anti-CTLA4inMOF) prevents the tumour occurrence, prolongs the survival rate and suppresses the tumour growth. Kaplan–Meier curve of tumour-free mice (left) and mice survival (middle), and tumour volume curve (right) after subcutaneously challenging E.G7-OVA cells into the right flank of vaccinated mice (n = 7 independent animals; left, middle, log-rank; right, two-way ANOVA). d–f Representative flow cytometry plots (d, e) and population (f) of Tetramer+CD8+ T cells in splenocytes and tumour sites at the endpoint (n = 4 independent animals, one-way ANOVA followed by Tukey’s multiple comparisons post hoc test; splenocytes, p < 0.0001; tumour, p = 0.0036). g IFN-γ and TNF-α contents in the spleen (1#, 2#, n = 6 independent animals; 3#, 4#, n = 7 independent animals; one-way ANOVA followed by Tukey’s multiple comparisons post hoc test; IFN-γ, p < 0.0001; TNF-α, p = 0.0058). All data (c, right panel; f, g) are presented as mean + S.D.

Back to article page